Rheumatology Advance Access originally published online on September 27, 2005
Rheumatology 2006 45(1):20-25; doi:10.1093/rheumatology/kei111
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
REVIEW |
Use and significance of anti-CCP autoantibodies in rheumatoid arthritis
Department of Biochemistry, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands.
Correspondence to: A. J. W. Zendman, Department of Biochemistry, NWI 161, Radboud University Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. E-mail: h.zendman@ncmls.ru.nl
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
One of the most common autoimmune diseases is rheumatoid arthritis (RA), affecting 0.5–1% of the population. This systemic disease is marked by chronic inflammation of synovial joints, which leads to destruction of cartilage and bone and eventually to disability of the patient [1]. Though not directly life-threatening, RA severely affects the quality of life of a patient and also has major economic consequences for society. Therefore, every attempt should be made to prevent the erosive processes to occur. Currently, the classification of RA relies mainly on the criteria described by the American College of Rheumatology (ACR) [2]. These criteria, originally formulated 50 yr ago and last adjusted in 1987, are based mainly on clinical parameters. Since these parameters are often only sufficiently fulfilled when the damaging effects of the inflammatory process are already in progress, this set of criteria is not very suitable for the early
|
From APF to CCP2 |
|---|
|
Anti-CCP2 autoantibodies as diagnostic markers |
|---|
Sensitivity/specificity
Early presence and predictive potential
|
Anti-CCP2 autoantibodies as a prognostic marker |
|---|
|
Effect of therapy on anti-CCP status |
|---|
|
Putative functional implications for anti-CCP |
|---|
|
Future perspectives |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A A Tieleman, A A d. Broeder, A-E van de Logt, and B G M van Engelen Strong association between myotonic dystrophy type 2 and autoimmune diseases J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1293 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Doodes, Y. Cao, K. M. Hamel, Y. Wang, B. Farkas, Y. Iwakura, and A. Finnegan Development of Proteoglycan-Induced Arthritis Is Independent of IL-17 J. Immunol., July 1, 2008; 181(1): 329 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-K. Koivula, E. Savolainen, O. Kaipiainen-Seppanen, H. Kautiainen, R. Luosujarvi, M. Hakala, and J. Risteli Sensitivity and specificity of autoantibodies binding to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series Rheumatology, May 1, 2008; 47(5): 656 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Anzilotti, L. Riente, F. Pratesi, D. Chimenti, A. Delle Sedie, S. Bombardieri, and P. Migliorini IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders Rheumatology, October 1, 2007; 46(10): 1579 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bobbio-Pallavicini, R. Caporali, C. Alpini, S. Avalle, O. M Epis, C. Klersy, and C. Montecucco High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor {alpha} inhibitors in rheumatoid arthritis Ann Rheum Dis, March 1, 2007; 66(3): 302 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Combination therapy for early rheumatoid arthritis DTB, November 1, 2006; 44(11): 81 - 85. [Abstract] [Full Text] [PDF]
|
|